Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
Systemic Therapy for Melanoma: ASCO Guideline Update.
СтатьяКлинические рекомендацииСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seth Rahul, Agarwala Sanjiv S, Messersmith Hans, Alluri Krishna C, Ascierto Paolo A, Atkins Michael B, Bollin Kathryn, Chacon Matias, Davis Nancy, Faries Mark B, Funchain Pauline, Gold Jason S, Guild Samantha, Gyorki David E, Kaur Varinder, Khushalani Nikhil I, Kirkwood John M, McQuade Jennifer Leigh, Meyers Michael O, Provenzano Anthony, Robert Caroline, Santinami Mario, Sehdev Amikar, Sondak Vernon K, Spurrier Gilliosa, Swami Umang, Truong Thach-Giao, Tsai Katy K, van Akkooi Alexander, Weber Jeffrey
Аннотация
PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma.
METHODS: American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature.
RESULTS: The updated review identified 21 additional randomized trials.
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C disease and adjuvant nivolumab plus ipilimumab was added as a potential option for stage IV disease. For patients with unresectable or metastatic cutaneous melanoma, nivolumab plus relatlimab was added as a potential option regardless of BRAF mutation status and nivolumab plus ipilimumab followed by nivolumab was preferred over BRAF/MEK inhibitor therapy. Talimogene laherparepvec is no longer recommended as an option for patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. Ipilimumab- and ipilimumab-containing regimens are no longer recommended for patients with BRAF-mutated disease after progression on other therapies.This full update incorporates the new recommendations for uveal melanoma published in the 2022 Rapid Recommendation Update.Additional information is available at www.asco.org/melanoma-guidelines.
METHODS: American Society of Clinical Oncology convened an Expert Panel and conducted an updated systematic review of the literature.
RESULTS: The updated review identified 21 additional randomized trials.
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C disease and adjuvant nivolumab plus ipilimumab was added as a potential option for stage IV disease. For patients with unresectable or metastatic cutaneous melanoma, nivolumab plus relatlimab was added as a potential option regardless of BRAF mutation status and nivolumab plus ipilimumab followed by nivolumab was preferred over BRAF/MEK inhibitor therapy. Talimogene laherparepvec is no longer recommended as an option for patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. Ipilimumab- and ipilimumab-containing regimens are no longer recommended for patients with BRAF-mutated disease after progression on other therapies.This full update incorporates the new recommendations for uveal melanoma published in the 2022 Rapid Recommendation Update.Additional information is available at www.asco.org/melanoma-guidelines.